Cytosorbents (CTSO) Change in Accured Expenses (2010 - 2026)
Cytosorbents (CTSO) posted Change in Accured Expenses of $92000.0 for Q1 2026, up 117.07% on a QoQ basis from -$539000.0 in Q4 2025, and up 125.07% year-over-year from $40876.5 in Q1 2025.
Cytosorbents (CTSO) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Cytosorbents' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $92000.0 for Q1 2026.
- Quarterly Change in Accured Expenses rose 125.07% year-over-year to $92000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$247000.0 (up 72.35% YoY) and the FY2025 annual result came in at -$706000.0, up 60.95% from the prior year.
- Change in Accured Expenses was $92000.0 for Q1 2026 at Cytosorbents, up from -$539000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.4 million in Q4 2024 and bottomed at -$1.3 million in Q1 2024.
- A 5-year average of -$239036.0 and a median of -$338765.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 490.9% — and 2023, when it surged 371.1%.
- Cytosorbents' Change in Accured Expenses stood at -$206441.0 in 2022, then soared by 371.1% to $559666.0 in 2023, then jumped by 142.64% to $1.4 million in 2024, then tumbled by 139.69% to -$539000.0 in 2025, then surged by 117.07% to $92000.0 in 2026.
- Business Quant data shows CTSO's Change in Accured Expenses at $92000.0 in Q1 2026, -$539000.0 in Q4 2025, and $193000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.47 Bn | 176.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 129.01 Bn | 126.14 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn | 123.00 Mn |
| 4 | Boston Scientific | 68.46 Bn | 67.01 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 48.40 Bn | 44.73 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn | 145.10 Mn |
| 7 | GE HealthCare Technologies | 28.36 Bn | 26.07 Bn | 1.98 Bn | -250.00 Mn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.46 Bn | 22.33 Bn | 2.07 Bn | 21.07 Mn |
| 10 | Cytosorbents | 22.59 Mn | 17.79 Mn | 6.13 Mn | 92,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92,000.00 |
| Mar 31, 2026 | 92,000.00 |
| Dec 31, 2025 | -539,000.00 |
| Dec 31, 2025 | -539,000.00 |
| Sep 30, 2025 | 193,000.00 |
| Sep 30, 2025 | 193,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Mar 31, 2025 | -367,000.00 |
| Mar 31, 2025 | -367,000.00 |
| Dec 31, 2024 | 1.36 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | -1.13 Mn |
| Sep 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | -750,276.00 |
| Jun 30, 2024 | -750,276.00 |
| Mar 31, 2024 | -1.28 Mn |
| Mar 31, 2024 | -1.28 Mn |
| Dec 31, 2023 | 559,666.00 |
| Dec 31, 2023 | 559,666.00 |